# Arcturus Therapeutics

Type: Company (ARCT)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/arcturus-therapeutics
Canonical HTML page: https://gethealthbrief.com/entity/arcturus-therapeutics

## Timeline

- **2026-03-03**: Q4 Earnings Release — Both companies scheduled to report full-year 2025 financial results.
- **2025-09-15**: ARCT-032 Phase 1b — Arcturus releases positive interim data for Cystic Fibrosis candidate.
- **2023-11-28**: Kostaive Approval — Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.

## Recent coverage (2 stories)

### Mixed Analyst Sentiment Hits Biotech: Apogee and Arcturus Under Scrutiny
2026-03-19 14:56:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.
Full story: https://gethealthbrief.com/story/biotech-analyst-activity-apogee-arcturus

### Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports
2026-03-02 22:53:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Full story: https://gethealthbrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.